6W9Z
De novo designed receptor transmembrane domains enhance CAR-T cytotoxicity and attenuate cytokine release
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | SYNCHROTRON |
Source details | AUSTRALIAN SYNCHROTRON BEAMLINE MX2 |
Synchrotron site | Australian Synchrotron |
Beamline | MX2 |
Temperature [K] | 100 |
Detector technology | PIXEL |
Collection date | 2018-11-19 |
Detector | DECTRIS EIGER X 16M |
Wavelength(s) | 0.95366 |
Spacegroup name | P 2 21 21 |
Unit cell lengths | 44.100, 56.205, 91.637 |
Unit cell angles | 90.00, 90.00, 90.00 |
Refinement procedure
Resolution | 39.738 - 2.700 |
R-factor | 0.2244 |
Rwork | 0.219 |
R-free | 0.27550 |
Structure solution method | MOLECULAR REPLACEMENT |
Starting model (for MR) | 5eh6 |
Data reduction software | XDS (Jan 26, 2018 BUILT=20180319) |
Data scaling software | Aimless (0.7.4) |
Phasing software | PHASER (2.8.2) |
Refinement software | PHENIX (1.16_3549) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 39.740 | 2.796 |
High resolution limit [Å] | 2.700 | 2.700 |
Rmerge | 0.070 | 0.855 |
Rmeas | 0.080 | 0.969 |
Rpim | 0.037 | 0.449 |
Number of reflections | 6655 | 444 |
<I/σ(I)> | 13.26 | 1.86 |
Completeness [%] | 96.1 | 68.62 |
Redundancy | 4.4 | 4.4 |
CC(1/2) | 0.999 | 0.615 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | LIPIDIC CUBIC PHASE | 6.7 | 293 | 40 mg/ml peptide in LCP 8 v/v 2-methyl-2,4-pentanediol 0.1 M ADA pH 6.7 0.4 M potassium nitrate 0.1 M tripotassium citrate |